Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of <scp>HIV</scp>‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists-Reference-Cited by-同舟云学术

Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists

Published:2024-07 Issue:7 Volume:44 Page:494-538
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Sherman Elizabeth M.¹²^ORCID,Agwu Allison L.³^ORCID,Ambrosioni Juan⁴⁵⁶^ORCID,Behrens Georg M. N.⁷⁸⁹^ORCID,Chu Carolyn¹⁰^ORCID,Collins Lauren F.¹¹^ORCID,Jimenez Humberto R.¹²¹³^ORCID,Koren David E.¹⁴^ORCID,McGorman Leslie¹⁵,Nguyen Nancy N.¹⁶^ORCID,Nicol Melanie R.¹⁷^ORCID,Pandit Neha Sheth¹⁸^ORCID,Pierre Natacha¹⁹^ORCID,Scarsi Kimberly K.²⁰^ORCID,Spinner Gary F.²¹,Tseng Alice²²²³^ORCID,Young Jeremy D.²⁴^ORCID,Badowski Melissa E.²⁵^ORCID

Affiliation:

1. Barry and Judy Silverman College of Pharmacy Nova Southeastern University Fort Lauderdale Florida USA

2. Division of Infectious Disease Memorial Healthcare System Hollywood Florida USA

3. Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore Maryland USA

4. HIV Unit and Infectious Disease Service Hospital Clinic and Fundació de Recerca Clínic Barcelona‐IDIBAPS Barcelona Spain

5. University of Barcelona Barcelona Spain

6. CIBERINFEC Instituto de Salud Carlos III Madrid Spain

7. Department of Rheumatology and Immunology Hannover Medical School Hannover Germany

8. German Center for Infection Research (DZIF), Partner Site Hannover‐Braunschweig Hannover Germany

9. Centre for Individualized Infection Medicine (CiiM) Hannover Medical School Hannover Germany

10. University of California San Francisco San Francisco California USA

11. Division of Infectious Diseases, Emory School of Medicine Grady Ponce de Leon Center Atlanta Georgia USA

12. Ernest Mario School of Pharmacy Rutgers University Piscataway New Jersey USA

13. Comprehensive Care Center St. Joseph's University Medical Center Paterson New Jersey USA

14. Temple University Health System Philadelphia Pennsylvania USA

15. American Academy of HIV Medicine Washington District of Columbia USA

16. Thomas J. Long School of Pharmacy University of the Pacific Stockton California USA

17. Department of Experimental and Clinical Pharmacology University of Minnesota College of Pharmacy Minneapolis Minnesota USA

18. Department of Practice, Sciences, and Health Outcomes Research University of Maryland Baltimore School of Pharmacy Baltimore Maryland USA

19. Department of Population Health Nursing Science, College of Nursing University of Illinois at Chicago Chicago Illinois USA

20. Department of Pharmacy Practice and Science, College of Pharmacy University of Nebraska Medical Center Omaha Nebraska USA

21. Southwest Community Health Center Bridgeport Connecticut USA

22. Immunodeficiency Clinic University Health Network Toronto Ontario Canada

23. Leslie Dan Faculty of Pharmacy University of Toronto Toronto Ontario Canada

24. Division of Infectious Diseases The Ohio State University Wexner Medical Center Columbus Ohio USA

25. College of Pharmacy University of Illinois at Chicago Chicago Illinois USA

Abstract

AbstractFive long‐acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV‐1 prevention or treatment—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV‐1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV‐1 treatment and prevention. In addition, future areas of research are also identified and discussed.

Publisher

Wiley

Reference200 articles.

1. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services [Internet].2022[cited 2022 Aug 5]. Available from:https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult‐adolescent‐arv/guidelines‐adult‐adolescent‐arv.pdf

2. Ibalizumab, a novel monoclonal antibody for the management of multidrug‐resistant HIV‐1 infection;Beccari MV;Antimicrob Agents Chemother,2019

3. WORLDWIDE REGISTRATION: Cabotegravir PrEP.ViiV Healthcare.2022.

4. Population council acquires the monthly dapivirine ring and other woman‐centered HIV prevention technologies from the international partnership for microbicides [Internet]. International Partnership for Microbicides.2022[cited 2023 Apr 6]. Available from:https://www.ipmglobal.org/content/population‐council‐acquires‐monthly‐dapivirine‐ring‐and‐other‐woman‐centered‐hiv‐prevention

5. Flip‐flop pharmacokinetics—delivering a reversal of disposition: challenges and opportunities during drug development;Yáñez JA;Ther Deliv,2011